Spyre Therapeutics, Inc.
Status: Publicly traded
Direct answer
Spyre Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SYRE.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both...
Can you invest in Spyre Therapeutics, Inc.?
Yes. Spyre Therapeutics, Inc. trades publicly on NASDAQ as SYRE.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Spyre Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.